All participants | No cardiotoxicity | Cardiotoxicity | P value | Reference ranges25 27 28 | |
N=40 | N=30 | N=10 | |||
LV ejection fraction (%) | 55.2 (51.3–61.2) | 58.5 (54.5–61.6) | 49.2 (45.5–49.9) | <0.001 | 51–70 |
LV end-diastolic volume, indexed to BSA (mL/m2) | 69.8 (62.9–82.1) | 66.7 (60.5–80.2) | 80.6 (68.6–91.1) | 0.034 | 54–94 |
LV end-systolic volume, indexed to BSA (mL/m2) | 30.3 (25.4–37.4) | 28.9 (23.3–34.9) | 40.9 (34.8–49.6) | <0.001 | 19–40 |
LV myocardial mass, indexed to BSA (g/m2) | 38.6 (35.9–44.2) | 38.5 (36.0–41.6) | 44.6 (35.8–50.3) | 0.22 | 29–55 |
RV ejection fraction (%) | 57.7 (53.2–62.9) | 59.6 (54.7–63.7) | 54.9 (51.1–57.6) | 0.061 | 47–68 |
RV end-diastolic volume, indexed to BSA (mL/m2) | 65.0 (56.8–72.2) | 64.3 (56.4–72.0) | 66.3 (59.7–77.9) | 0.33 | 53–99 |
RV end-systolic volume, indexed to BSA | 26.7 (22.8–32.0) | 25.5 (21.3–31.6) | 30.4 (28.1–33.0) | 0.053 | 17–46 |
LV global circumferential strain by FT (%) | −18.8 (−20.7 to −17.6) | −19.3 (−21.1 to −18.4) | −17.2 (−17.9 to −15.3) | 0.002 | −24 to −13 |
LV global longitudinal strain by FT (%) | −16.0 (−17.1 to −13.7) | −16.2 (−17.2 to −14.8) | −13.7 (−16.4 to −11.8) | 0.049 | −27 to −11 |
LV global circumferential strain by DENSE (%) | −18.1 (−20.0 to −17.1) | −18.2 (−20.4 to −17.2) | −17.5 (−18.1 to −15.3) | 0.065 | −24 to −12 |
LV global longitudinal strain by DENSE (%) | −7.3 (−9.5 to −5.0) | −8.3 (−9.5 to −5.6) | −5.3 (−7.8 to −3.0) | 0.034 | −19 to −11 |
LV global T1 (ms) | 1205.1 (1174.7–1222.5) | 1209.2 (1180.1–1223.6) | 1200.4 (1167.3–1208.9) | 0.18 | 1107–1234 |
Global ECV (%) | 27.1 (25.8–28.3) | 27.6 (26.5–28.6) | 26.9 (18.7–27.5) | 0.17 | >27.4 |
LV global T2 (ms) | 40.7 (39.3–42.5) | 41.1 (39.3–42.5) | 39.5 (38.9–42.0) | 0.42 | 35–44 |
Data are presented as median+IQR.
Bold values are statistically signficant.
BSA, body surface area; DENSE, displacement encoding with stimulated echoes; ECV, extracellular volume; FT, feature tracking; LV, left ventricular; RV, right ventricular.